Appendix 4: Comparison of Guidance Documents

Key points/recommendations noted in major documents	Supported by	Note
Shared decision making with patient	UK	
CFS/ME symptoms ¹ / diagnostic criteria	Various	Evidence to substantiate any case definition/set of criteria is weak.
		No studies providing basis of case definition ²
Diagnosis: when symptoms have persisted for 4months (adult) / 3months (child)	UK	Evidence on diagnostic testing is weak. NZGG: agreement on fatigue persistence with >6 months (adult) 3 months (child) being the most common duration given.
=> 6months(adult)	Australia; Canada; Netherlands	
Diagnosis: re tests that should be done (n=13)	Various	NZGG indicates agreement for routine tests to include: full blood count; TSH; biochemistry profile and serum electrolysis & urinalysis.
		Additional tests include: Hep B&C thyroid function test, and any others suggested by history or symptoms.
Conditions considered in differential diagnosis differs:		
14+ psychiatric disorders	Australia	Taken from NZGG (2004)

¹ Fatigue that is new onset; is persistent and/or recurrent; is unexplained by other conditions; has resulted in substantial reduction in activity level; is characterised by post-exertion malaise AND one or more of : difficulty with sleeping; muscle and/or joint pain without inflammation; headaches; painful lymph nodes without pathological enlargement; sore throat; cognitive dysfunction; symptoms exacerbated by physical exertion; general malaise of flu-like symptoms; dizziness and/or nausea; or palpitations.

² Mulrew, C.D., Ramirez, G., Cornell, J.E. & Allsup, K. (2001) 'Defining and managing chronic fatigue syndrome' *Evidence Rep Technology Assessment* Summer (42): 1-4

12+ psychiatric disorders		
32 including psychiatric disorders	US	
8+ psychiatric disorders and	Canada	
substance abuse		
Specialist diagnostic testing for	US	
adolescents & children		
Advice on symptom management	UK	
should not be delayed until		
diagnosis established		
Information & training patients and	UK	
carers.	SSLWG (p.8)	
	NZGG: info to	
	patients and	
	carers part of	
	shared	
[info and support re illness,	management.	
healthcare, and assistance re		
work/education]	AfME (p.14)	
Take account of severity, patient's	UK	
age and previous treatments		
Recognise patient's right to	UK	
refuse/withdraw from treatment		
Establish supportive/collaborative	UK; Australia;	
relationship with	Netherlands	
patient/carer/family		
Care co-ordinated for each patient	UK	
by named health professional		
Diagnostic/therapeutic options to	UK	
suit individual need	NZGG	
	SSLWG	
Management:		
Diet	UK	
[healthcare professionals should		

provide general advice re importance of good diet but seek advice from dietician if patient wishes to undertake special diet]		
Drug treatment [of the three noted by NZGG NICE cite only tricyclic antidepressants]	UK NZGG: include tricyclic antidepressants; NSAIDS and other analgesics, and muscle relaxants.	 NICE (UK) state that no research evidence supports people's experience of greater intolerance to drug treatments including more severe side effects. NZGG: common agreement that people with CFS/ME 'are often susceptible to medication side effects'.
Nausea [Should be managed conventionally]	UK	
Sleep [advise on sleep hygiene]	UK SSLWG NZGG	
Rest [rest periods part of management plan. Should be reviewed regularly]	UK	
Relaxation [help with pain; sleep problems and co-morbid stress/anxiety. Can be incorporated into rest periods]	UK	
Pacing	Canada Australia	Patient confidence in Pacing noted by : SSLWG(p.15) (UK); AfME (p.32) (UK) ; Gibson Enquiry (UK) ; and Netherlands The NICE Guidelines (UK) view is that people should be advised of

FINAL

		insufficient research to support benefit/harm of pacing.
Equipment (e.g. wheelchair) recommended if maintains independence and QoL.	UK	
Education (liaise with education services re fitness for school/coll/uni)	UK	
Employment (liaise with employers re fitness for work)	UK	
Complementary therapies/medicines	UK SSLWG (p.17)	Lack of empirical trials (SSLWG)
[insufficient evidence to support]		US guidance suggests some benefits.
Referral to specialist [should be based on need –	UK SSLWG (p.14)	Evidence weak. GDG group consensus.
decision to refer should be made jointly – should be offered immediately to those with severe CFS/ME symptoms]	NZGG: referral may be necessary as part of diagnostic workup.	NZGG: specialist in put may need to be multidisciplinary.
Referral to paediatrician for children	UK SSLWG (p.14) NZGG	
Specialist care (management & treatment):	UK SSLWG: level of specialist services required in Scotland	UK notes need to avoid referring to specialist management programmes delivered by practitioners with no experience of ME-CFS.
Individualised plan	UK SSLWG (p.11); AfME (p.18)	

	NZGG	
Aim at physical and emotional	UK	
	NZGG, SSLWG	
impact on symptoms Patient should be well-informed	UK	
Palient should be well-informed	-	
	AfME (p.18)	
	NZGG: info to	
	patients and	
	carers part of	
	shared	
	management	
Patient autonomy	AfME (p.18)	Implied but not emphasised
Goals setting by patient	AfME (p.18)	Implied but not emphasised
CBT (offered to those with mild-	UK	Further research required (SSLWG)
moderate)	SSLWG (p.15)	Netherlands note limited benefit and modifications for some
[patient should be in charge of		
aims of programme]		UK notes the need for specific ME-CFS experience by the professional
[therapeutic goals should be		offering CBT. This should be tailored to the patient's need and level of
agreed between patient and health		functioning
professional]		
GET (offered to those with mild-	UK	Long term data is limited (SSLWG)
moderate)		Netherlands: CBT/GET considered together – non-commital on
		effectiveness of GET
		NZGG includes note that graded exercise programmes recently found to
		be harmful.
		UK notes the need for GET to be delivered by a therapist with experience
		in ME-CFS management. This should be tailored to the patient's need,
		circumstances and level of functioning.
Activity management	SSLWG (p.16)	UK specifies Activity Management as it is used within the NICE Guideline
	UKŰ	
Drug therapies		
Pain management:		
-start with lower doses	UK; SSLWG	
-multiple non-pharmacological	UK; US; Australia	

and/or psychological approaches may be helpful -lifestyle management with no mention of psychological approach -efficacy of alternative therapies cited	Canada US	
Setbacks/relapses	SSLWG (p19)	
-should be planned for	(i)	
-should be managed	UK	
Review/ongoing management	UK	
[should be regular and structured]	SSLWG	
Patients with severe CFS/ME: - require specialist management - requires community involvement/home visiting	UK SSLWG (p.18)	
Self-monitoring/patient diaries to	Canada	
help management	Australia	

Reference Note: documents cited in this table

Australia: Royal Australian College of Physicians (2002) *Chronic Fatigue Syndrome. Clinical Practice Guidelines*, Health Policy Unit, Royal Australian College of Physicians

South Australian Department of Human Services (2004) *Myalgic Encephalopathy (ME) /Chronic Fatigue Syndrome (CFS) Management Guidelines for General Practice*

AfME: Action for ME (2007) Scotland M.E.? CFS Scoping Exercise Report

Canada

Australia

UK Comparative document covering all four countries:

FINAL

- US New Zealand Guidelines Group (NZGG) (2004), Chronic Fatigue comparison matrix Available URL: http://www.nzgg.org.nz/guidelines/0084/040518 matrix.pdf [Accessed 13 May 2008]
- Netherlands: Gezonheidsraad. Health Council of the Netherlands (2005) Chronic Fatigue Syndrome. Advisory Report to the Minister of Health, Welfare & Sport
- NZGG: New Zealand Guidelines Group (NZGG) (2004), Chronic Fatigue comparison matrix Available URL: http://www.nzgg.org.nz/guidelines/0084/040518 matrix.pdf [Accessed 13 May 2008]
- SSLWG: Scottish Short Life Working Group (SSLWG) (2002) Chronic Fatigue syndrome / myalgic encephalomyetis (CFS/ME). Outline for Development of Services for CFS/ME in Scotland.Report of the Scottish Short Life Working Group
- UK: National Institute for Clinical Excellence (NICE) (2007), *Chronic fatigue syndrome / myalgic encephalomyelitis(or encephalopathy). Diagnosis and management of CFS/ME in adults and children. Quick Reference Guide*, NHS National Institute for Clinical Excellence; Turnbull, N., Shaw, E.J., Baker, R., Dunsdon, S., Costin, N., Kuntze, S. and Norman, R. (2007) *Chronic Fatigue syndrome / myalgic encephalomyelitis(or encephalopathy): diagnosis and management of chronic fatigue syndrome / myalgic encephalomyelitis(or encephalopathy): diagnosis and management of chronic fatigue syndrome / myalgic encephalomyelitis(or encephalopathy) in adults and children* [Full guidelines]